Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
药物研究 抗生素和抗病毒
/
抗感染
小分子阳性药 功能 结构
/
核苷类
巨细胞病毒 抗病毒
/ Valganciclovir HCl

缬更昔洛韦盐酸盐 /Valganciclovir HCl {[allProObj[0].p_purity_real_show]}

货号：A247777 同义名： Valganciclovir (hydrochloride);Ro 107-9070/194

Valganciclovir HCl is the L-valyl ester of ganciclovir, is a prodrug for ganciclovir with antiviral activity used to treat cytomegalovirus infections.

Valganciclovir HCl 化学结构 CAS号：175865-59-5
Valganciclovir HCl 化学结构
CAS号：175865-59-5
Valganciclovir HCl 3D分子结构
CAS号：175865-59-5
Valganciclovir HCl 化学结构 CAS号：175865-59-5
Valganciclovir HCl 3D分子结构 CAS号：175865-59-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Valganciclovir HCl 纯度/质量文件 产品仅供科研

货号：A247777 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

Valganciclovir HCl 生物活性

描述 Cytomegalovirus (CMV) is a herpes virus that causes disease in severely immunocompromized patients. The ganciclovir prodrug valganciclovir, avalyl ester of ganciclovir, is rapidly converted to ganciclovir during the first pass process in the gut wall and is used to treat CMV infection. In vitro, valganciclovir inhibited the uptake of glycylsarcosine in a dose-dependent manner with IC50 values of 1.69 ± 0.30 mM in Caco-2 cells and 0.046 ± 0.005 mM in SKPT cells, respectively. Likewise, it inhibited the uptake of the dipeptide in a dose-dependent manner with IC50 values of 2.84 ± 0.42 mM in PEPT1-expressing cells and 0.176 ± 0.012 mM in PEPT2-expressing cells[3]. For patients with CMV viremia, valganciclovir (900 mg b.i.d. for 7 days) was effective as pre-emptive therapy with rate of viral clearance at 28 days of 89.5%[4].

Valganciclovir HCl 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02227641 Patients Undergoing Allogeneic... 展开 >> Stem Cell Transplantation 收起 << Phase 1 Phase 2 Unknown March 2017 Germany ... 展开 >> Medical Center Augsburg Recruiting Augsburg, Germany, 86156 Contact: Christoph Schmid, MD, PhD    0049 821 4002736       Principal Investigator: Christoph Schmid, MD, PhD          Charité University Hospital Berlin Recruiting Berlin, Germany, 13353 Contact: Armin H Gerbitz, MD, PhD    ++49 30 450565256    armin.gerbitz@charite.de    Contact: Lutz Uharek, MD, PhD       lutz.uharek@charite.de    Sub-Investigator: Lutz Uharek, MD, PhD          Principal Investigator: Armin Gerbitz, MD, PhD          Universitiy Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Anita Kremer, MD, PhD    ++49 9131 8543183    anita.kremer@uk-erlangen.de    Contact: Bernd Spriewald, MD, PhD    ++49 9131 8543116    bernd.spriewald@uk-erlangen.de    Sub-Investigator: Katja San Niccolo, MD          University of Mainz Recruiting Mainz, Germany, 55131 Contact: Eva Wagner, MD          Principal Investigator: Eva Wagner, MD          University of Munich LMU Recruiting Munich, Germany, 81377 Contact: Johanna Tischer, MD    0049 89 70954240       Principal Investigator: Johanna Tischer, MD          University of Regensburg Not yet recruiting Regensburg, Germany, 93053 Contact: Ernst Holler, MD, PhD    0049 941 9445570       Principal Investigator: Ernst Holler, MD, PhD 收起 <<
NCT00078559 Kidney Transplantation ... 展开 >> Kidney Disease 收起 << Phase 1 Phase 2 Completed - United States, Wisconsin ... 展开 >> University of Wisconsin - Department of Medicine Madison, Wisconsin, United States, 53792-1735 收起 <<
NCT02188719 Liver Transplantation Phase 1 Recruiting January 2022 United States, California ... 展开 >> University of California, San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Monique Koenigsberg    415-502-3016    Monique.Koenigsberg@ucsf.edu    Principal Investigator: Sandy Feng, MD, PhD          United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 55905 Contact: Patrice Al-Saden    312-503-1058    palsaden@northwestern.edu    Principal Investigator: Josh Levitsky, MD          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Julie Gecox Hanson, CCRP    507-293-6592    Gecox.Julie@mayo.edu    Principal Investigator: Timucin Taner, MD, PhD 收起 <<

Valganciclovir HCl 参考文献

[1]Chawla JS, Ghobadi A, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun;14(3):259-67.

[2]Sugawara M, Huang W, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.

[3]Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9

[4]Chawla JS, Ghobadi A, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun;14(3):259-67

Valganciclovir HCl 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.79mL

2.56mL

1.28mL

25.59mL

5.12mL

2.56mL

Valganciclovir HCl 技术信息

CAS号175865-59-5
分子式C14H23ClN6O5
分子量 390.823
别名 Valganciclovir (hydrochloride);Ro 107-9070/194;Valganciclovir hydrochloride
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C
溶解度

DMSO: 50 mg/mL(127.94 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(127.94 mM)
动物实验配方

Tags: Valganciclovir | 175865-59-5 | CMV | Cytomegalovirus | Anti-infection | CMV | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Valganciclovir HCl 纯度/质量文件 | Valganciclovir HCl 生物活性 | Valganciclovir HCl 临床数据 | Valganciclovir HCl 参考文献 | Valganciclovir HCl 实验方案 | Valganciclovir HCl 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z